Breaking Finance News

FBR & Co. covered Alnylam Pharma (NASDAQ:ALNY), bumping down its stock price target to $100.00 today

Displaying a price of $70.30, Alnylam Pharma (NASDAQ:ALNY) traded 2.52% higher on the day. With the last close up 5.78% from the two hundred day average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $72.86 and a 200-day moving average of $66.46. 1,965,395 shares of the stock were exchanged, up from an avg. volume of 643,269

In a statement issued on 10/6/2016 FBR & Co. dropped the target of Alnylam Pharma (NASDAQ:ALNY) from $180.00 to $100.00 stating a potential upside of 0.42%.

On 9/29/2016, Janney Capital reported about Alnylam Pharma (NASDAQ:ALNY) bumped up the target price from $0.00 to $74.00. At the time, this suggested a downside of -0.03%.

Recent Performance Chart

Alnylam Pharma (NASDAQ:ALNY)

With a market capitalization of $0, Alnylam Pharma has with a one year low of $49.96 and a 52 week high of $110.75 .

Also covering Alnylam Pharma's price target, a total of 11 analysts have released a report on Alnylam Pharma. The 12-month stock price target is $117.09 with 3 brokerages rating the stock a strong buy, 8 firms rating the company a buy, two analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero brokers rating the stock a sell.

Brief Synopsis On Alnylam Pharma (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.